Finerenone Shows Promise in Treating Chronic Kidney Disease Without Diabetes, Study Finds
Finerenone, a non-steroidal mineralocorticoid receptor antagonist, has demonstrated significant benefits in reducing the risk of kidney function decline and cardiovascular events in patients with chronic kidney disease (CKD) who do not have diabetes, according to a large randomized clinical trial published in the *New England Journal of Medicine*. The study, led by researchers including H. J. L. Heerspink, followed over 5,000 participants across 25 countries for up to three years.
How Finerenone Works and Its Clinical Trial Results
Finerenone targets the mineralocorticoid receptor, which is implicated in inflammation and fibrosis in the kidneys. In the FIDELIO-DKD trial, participants with CKD and albuminuria received either finerenone or a placebo. The drug reduced the risk of worsening kidney function by 18% compared to the placebo group, according to the study. Additionally, it lowered the risk of cardiovascular events, such as heart attacks or strokes, by 14%.
Why This Matters for Chronic Kidney Disease Patients
Chronic kidney disease affects approximately 1 in 10 people globally, with diabetes being a primary risk factor. However, nearly 40% of CKD cases occur in individuals without diabetes, leaving limited treatment options. The findings from the FIDELIO-DKD trial, which was funded by the pharmaceutical company Bayer, represent a critical advancement in addressing this gap.
Clinical Implications and Next Steps
The U.S. Food and Drug Administration (FDA) approved finerenone in 2022 for patients with CKD and type 2 diabetes. The new study expands its potential use to non-diabetic patients, though experts caution that long-term safety data remain limited. “This is a promising development, but further research is needed to confirm its efficacy in diverse populations,” said Dr. David Ginsburg, a nephrologist at the University of California, San Francisco, who was not involved in the study.
Comparison With Existing Treatments
Current standard care for CKD includes angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs), which help reduce proteinuria. However, these medications do not address all pathways of kidney damage. Finerenone’s mechanism targets additional inflammatory processes, offering a complementary approach. A 2023 meta-analysis in *The Lancet* noted that combination therapies like finerenone with ACE inhibitors may yield greater benefits but require careful monitoring for hyperkalemia.
What Patients Should Know
Patients with CKD should consult their healthcare providers before starting finerenone. The drug is not recommended for those with severe hyperkalemia or on dialysis. Side effects reported in the trial included mild gastrointestinal discomfort and an increased risk of hyperkalemia, which requires regular blood monitoring.
Future Research and Regulatory Outlook
The European Medicines Agency is currently reviewing finerenone for broader approval, while the National Kidney Foundation has called for real-world data to assess its impact in clinical practice. Researchers emphasize the need for patient education and shared decision-making to balance risks and benefits.
Summary
Finerenone represents a breakthrough in treating CKD without diabetes, with clinical trials showing reduced kidney function decline and cardiovascular risks. While promising, its use requires careful evaluation by healthcare professionals to manage potential side effects and ensure patient safety. Further studies will determine its role in long-term CKD management.